Can early chemo beat the clock against colon cancer?

NCT ID NCT01460589

Ongoing Disease control Sponsor: Kyungpook National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether starting chemotherapy 10 to 14 days after surgery for stage III colon cancer is better than waiting the usual 2 weeks or more. About 300 patients are taking part to see if earlier treatment improves survival and lowers the chance of cancer coming back. The trial also checks for side effects and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FOLFOX chemotherapy (oxaliplatin, leucovorin, 5-FU)
What this could lead to: If early chemotherapy works better, it could become a new standard to reduce cancer recurrence and improve survival for stage III colon cancer patients.
What could go wrong: This is a moderate-sized phase 3 trial, but results may not apply to all patients. Early chemo could increase side effects or complications without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON CANCER

Contacts and locations

Locations

Jun Seok Park

Daegu, South Korea
Kyungpook National University Medical center

Daegu, 41404, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.